Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from...

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Survivors of cardiac arrest due to ventricular arrhythmias require effective long-term management.
• Antiarrhythmic drug therapy and implantable cardioverter-defibrillators (ICDs) are primary treatment options.

Purpose of the Study:

• To compare the efficacy of ICD therapy versus antiarrhythmic drugs in reducing all-cause mortality in cardiac arrest survivors.
• To evaluate long-term survival outcomes in patients receiving ICDs or drug therapy.

Main Methods:

• A prospective, multicenter, randomized trial comparing ICDs to amiodarone or metoprolol.
• Patients were randomized with a 1:3 ratio for ICD versus drug therapy.
• The primary endpoint was all-cause mortality, with a minimum 2-year follow-up for all participants.

Main Results:

• Over a mean follow-up of 57 months, crude death rates were 36.4% for ICDs and 44.4% for amiodarone/metoprolol.
• Overall survival was higher in the ICD group, though not statistically significant (P=0.081).
• ICD therapy showed a 23% reduction in all-cause mortality compared to drug therapy during long-term follow-up.

Conclusions:

• ICD therapy is associated with a trend toward reduced all-cause mortality in cardiac arrest survivors compared to amiodarone/metoprolol.
• The survival benefit of ICDs appears more pronounced within the first five years following the index cardiac event.